AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for SLIT-ROBO Rho GTPase-activating protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q7Z6B7

UPID:

SRGP1_HUMAN

Alternative names:

Rho GTPase-activating protein 13

Alternative UPACC:

Q7Z6B7; Q9H8A3; Q9P2P2

Background:

SLIT-ROBO Rho GTPase-activating protein 1, alternatively known as Rho GTPase-activating protein 13, plays a pivotal role in cellular processes by acting as a GTPase-activating protein for RhoA and Cdc42 small GTPases. It is instrumental in neuronal migration, mediating the repulsive signaling of Robo and Slit proteins, with SLIT2 enhancing its interaction with ROBO1 to inactivate CDC42.

Therapeutic significance:

The protein's association with non-medullary thyroid cancer, a prevalent form of thyroid cancer, underscores its potential as a therapeutic target. Understanding the role of SLIT-ROBO Rho GTPase-activating protein 1 could open doors to novel therapeutic strategies for managing this disease.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.